Jiangsu Hengrui Pharmaceuticals Co.,Ltd (SHA:600276)

Market Cap	412.52B
Revenue (ttm)	30.98B
Net Income (ttm)	7.47B
Shares Out	6.62B
EPS (ttm)	1.16
PE Ratio	53.51
Forward PE	40.63
Dividend	0.20 (0.32%)
Ex-Dividend Date	May 23, 2025

Volume	20,277,610
Average Volume	36,910,777
Open	62.36
Previous Close	62.09
Day's Range	61.61 - 62.36
52-Week Range	42.40 - 74.04
Beta	0.42
RSI	47.09
Earnings Date	Apr 19, 2026

About SHA:600276

Jiangsu Hengrui Pharmaceuticals Co.,Ltd, a pharmaceutical company, researches, develops, manufactures, and commercializes medicines to address unmet clinical needs in China and internationally. It develops medicines in the areas of oncology, metabolic and cardiovascular, immunological and respiratory, neuroscience, pain management, infectious, respiratory system, hematological, ophthalmology, and autoimmune and other diseases. The company was founded in 1970 and is headquartered in Lianyungang, China.

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1970
• Employees: 20,238
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600276

Financial Performance

In 2024, SHA:600276's revenue was 27.98 billion, an increase of 22.63% compared to the previous year's 22.82 billion. Earnings were 6.34 billion, an increase of 47.28%.